CY1124635T1 - Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα - Google Patents

Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα

Info

Publication number
CY1124635T1
CY1124635T1 CY20201100589T CY201100589T CY1124635T1 CY 1124635 T1 CY1124635 T1 CY 1124635T1 CY 20201100589 T CY20201100589 T CY 20201100589T CY 201100589 T CY201100589 T CY 201100589T CY 1124635 T1 CY1124635 T1 CY 1124635T1
Authority
CY
Cyprus
Prior art keywords
active agent
pharmaceutical compositions
spray
particle size
particles
Prior art date
Application number
CY20201100589T
Other languages
English (en)
Inventor
Maynard Emanuel Lichty
Garry T. Gwozdz
Original Assignee
Besins Healthcare Luxembourg Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Luxembourg Sarl filed Critical Besins Healthcare Luxembourg Sarl
Publication of CY1124635T1 publication Critical patent/CY1124635T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Παρέχονται στο παρόν ξηρές φαρμακευτικές συνθέσεις κατάλληλες για διαβλεννογονική παράδοση, που περιέχουν ξηρά σωματίδια, όπως ξηρανθέντα με ψεκασμό σωματίδια, που περιλαμβάνουν νανοσωματίδια φαρμακευτικώς δραστικού παράγοντα, συνδετικό υλικό και φαρμακευτικώς αποδεκτό φορέα, όπου τα νανοσωματίδια δραστικού παράγοντα έχουν διάμετρο μέσου μεγέθους σωματιδίων πριν την επεξεργασία μικρότερη από περίπου 1 μm, και όπου ως και 10% των ξηρανθέντων με ψεκασμό σωματιδίων έχουν μέγεθος σωματιδίων μικρότερο από 10 μm• τουλάχιστον το 50% των ξηρανθέντων με ψεκασμό σωματιδίων έχουν μέγεθος σωματιδίου τουλάχιστον περίπου 15 μm• και τουλάχιστον το 90% των ξηρανθέντων με ψεκασμό σωματιδίων έχουν μέγεθος σωματιδίων ως περίπου 55 μm. Παρέχονται επίσης μέθοδοι για την παρασκευή τέτοιων φαρμακευτικών συνθέσεων και θεραπευτικών μεθόδων που περιλαμβάνουν διαβλεννογονική χορήγηση των συνθέσεων, όπως ενδορινικά ή ενδοκολπικά, ή με άλλες οδούς χορήγησης.
CY20201100589T 2013-03-04 2020-06-25 Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα CY1124635T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772095P 2013-03-04 2013-03-04
PCT/US2014/019833 WO2014137877A1 (en) 2013-03-04 2014-03-03 Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles

Publications (1)

Publication Number Publication Date
CY1124635T1 true CY1124635T1 (el) 2022-03-24

Family

ID=47901822

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100589T CY1124635T1 (el) 2013-03-04 2020-06-25 Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα

Country Status (23)

Country Link
US (2) US10695295B2 (el)
EP (1) EP2964199B1 (el)
JP (1) JP6564708B2 (el)
CN (1) CN105307639B (el)
AU (1) AU2014226192B2 (el)
BR (1) BR112015021525B1 (el)
CA (1) CA2901015A1 (el)
CY (1) CY1124635T1 (el)
DK (1) DK2964199T3 (el)
ES (1) ES2804702T3 (el)
HR (1) HRP20201103T1 (el)
HU (1) HUE050050T2 (el)
IL (1) IL240867B (el)
LT (1) LT2964199T (el)
MX (1) MX375187B (el)
PL (1) PL2964199T3 (el)
PT (1) PT2964199T (el)
RS (1) RS60481B1 (el)
RU (1) RU2715714C2 (el)
SI (1) SI2964199T1 (el)
SM (1) SMT202000349T1 (el)
WO (1) WO2014137877A1 (el)
ZA (1) ZA201505852B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014226192B2 (en) 2013-03-04 2018-07-26 Besins Healthcare Luxembourg Sarl Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
WO2018025089A2 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Pharmaceutical compositions
WO2018213452A1 (en) * 2017-05-19 2018-11-22 Jackson Milton S Appetite suppressant
JP7453770B2 (ja) * 2019-10-25 2024-03-21 松本油脂製薬株式会社 複合粒子及びその製造方法
WO2022269556A1 (en) * 2021-06-25 2022-12-29 Nicoventures Trading Limited Oral products and method of manufacture

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
FR2575678B1 (fr) 1985-01-04 1988-06-03 Saint Gobain Vitrage Ejecteur pneumatique de poudre
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
CN1155368C (zh) * 1996-02-27 2004-06-30 帝人株式会社 鼻腔给药的粉剂组合物
EP1108423B1 (en) 1998-08-26 2005-03-30 Teijin Limited Powdery pernasal compositions
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
EA008242B1 (ru) 1999-12-08 2007-04-27 Фармация Корпорейшн Композиции на основе ингибитора циклооксигеназы-2 с быстро наступающим терапевтическим действием и способы лечения заболеваний
JP4721212B2 (ja) 2001-07-05 2011-07-13 株式会社新日本科学 インスリンの経鼻投与用組成物
CN1176649C (zh) 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
CA2512559A1 (en) 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US7947308B2 (en) 2005-07-20 2011-05-24 Raimar Loebenberg Effervescent powders for inhalation
JP2009519972A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
TW200817047A (en) 2006-04-03 2008-04-16 Teva Pharma Drug microparticles
GB0625322D0 (en) 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
GB0716907D0 (en) 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
US20110250274A1 (en) * 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
EP2429495A4 (en) 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITION WITH IMPROVED PHARMACOKINETICS
AU2010253770B9 (en) * 2009-05-29 2015-02-12 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
US20110262502A1 (en) 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
CA2796646A1 (en) * 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
WO2012051426A2 (en) 2010-10-15 2012-04-19 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
EP2540281A1 (en) * 2011-06-30 2013-01-02 LEK Pharmaceuticals d.d. Solid self-microemulsifying systems
AU2014226192B2 (en) 2013-03-04 2018-07-26 Besins Healthcare Luxembourg Sarl Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles

Also Published As

Publication number Publication date
JP6564708B2 (ja) 2019-08-21
CN105307639B (zh) 2020-06-30
PT2964199T (pt) 2020-05-12
JP2016510742A (ja) 2016-04-11
LT2964199T (lt) 2020-08-10
IL240867A0 (en) 2015-10-29
AU2014226192B2 (en) 2018-07-26
AU2014226192A1 (en) 2015-09-03
BR112015021525B1 (pt) 2022-06-14
IL240867B (en) 2020-11-30
WO2014137877A1 (en) 2014-09-12
US10918601B2 (en) 2021-02-16
MX2015011624A (es) 2015-12-17
AU2014226192A8 (en) 2016-04-21
CA2901015A1 (en) 2014-09-12
DK2964199T3 (da) 2020-06-15
BR112015021525A2 (pt) 2017-07-18
US10695295B2 (en) 2020-06-30
SI2964199T1 (sl) 2020-10-30
SMT202000349T1 (it) 2020-09-10
EP2964199B1 (en) 2020-04-22
PL2964199T3 (pl) 2021-01-25
RU2015141792A (ru) 2017-04-07
EP2964199A1 (en) 2016-01-13
US20140248367A1 (en) 2014-09-04
RU2715714C2 (ru) 2020-03-03
ZA201505852B (en) 2017-07-26
US20200390706A1 (en) 2020-12-17
MX375187B (es) 2025-03-06
HUE050050T2 (hu) 2020-11-30
ES2804702T3 (es) 2021-02-09
RU2015141792A3 (el) 2018-03-01
RS60481B1 (sr) 2020-08-31
CN105307639A (zh) 2016-02-03
HRP20201103T1 (hr) 2021-02-05

Similar Documents

Publication Publication Date Title
CY1123937T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
MX2017000080A (es) Conjugados y particulas direccionados y formulaciones de estos.
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
AR091006A1 (es) Formulaciones de testosterona proliposomal
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
MX2015010829A (es) Compuestos terapeuticos y sus usos.
CO7160008A2 (es) Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
TN2015000135A1 (en) Modified release formulations for oprozomib
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
MX375187B (es) Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo ligadas a partículas portadoras.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
EA201401309A1 (ru) Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
MX2015010486A (es) Composicion masticable para administracion oral y proceso para preparar la misma.
IN2013MU01177A (el)
WO2014165829A3 (en) Nanoparticle formulations